Global InformationSuvratoxumab information
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Staphylococcus aureus alpha toxin |
| Clinical data | |
| Other names | MEDI4893 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C6556H10114N1730O2100S44 |
| Molar mass | 148179.68 g·mol−1 |
Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.
This drug was developed by MedImmune[2]
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.